ArticleClinical ophthalmology (Auckland, N.Z.)2026
Safety and Efficacy of Optimal Keratoplasty in Reduction of Hyperopia and Hyperopic Presbyopia: A Retrospective Observational Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the safety and efficacy of the VIS Optimal Keratoplasty device and procedure for treating eyes with hyperopia and hyperopic presbyopia to achieve uncorrected distance visual acuity (UDVA) and uncorrected near visual acuity (UNVA) improvements. Setting: Bahamas Vision Centre, Nassau, New Providence, The Bahamas. Methods: 114 eyes of 57 patients with low to moderate hyperopic presbyopia (MRSE = 0.88 to 3.25 D; mean add ± standard deviation (SD) = 2.08 ± 0.43 D) received primary treatments (Txs) by the VIS NTK Optimal Keratoplasty device; 44 and 22 patients also received secondary and ternary Txs, respectively. Patients were treated to produce best UDVA and best UNVA in both eyes using a multifocal vision protocol. Safety and efficacy measures with follow-up (f/u) extending to 24 months post-Tx were analyzed. Results: Safety - There were no clinically significant adverse events or complications. Efficacy - Geometric mean (gm) ± SD binocular UDVA improvements corresponded to 3.6 ± 3.9 lines gained at 1 day post-primary Tx ( Conclusions: Optimal keratoplasty appears to be safe and efficacious for improving both UDVA and UNVA in eyes with hyperopic presbyopia, The procedure is noninvasive, simple, rapid, comfortable and repeatable. UDVA improvement is long lasting (2 years or more), although UNVA improvement is temporary. Additional optimal keratoplasty Txs can be repeated whenever needed to maintain functional UNVA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.